---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-26-000023"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:32:33.521786+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xencor receives Genentech/Roche termination notice for collaboration; effective Sept 4, 2026

## Summary
- Genentech terminated Amended and Restated Collaboration & License Agreement for convenience, effective September 4, 2026.
- Sole active product, efbalropendekin alfa, was removed from Roche's pipeline in January 2025.
- Xencor ceased cost-sharing in H1 2024; Genentech assumed sole responsibility for development activities.
- Termination had been anticipated after Roche's January 2025 pipeline announcement.

## SEC filing metadata
- accession: 0001326732-26-000023
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673226000023/0001326732-26-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673226000023/xncr-20260304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-26-000023
- JSON: https://secwatch.observer/filing/0001326732-26-000023.json
- Plain text: https://secwatch.observer/filing/0001326732-26-000023.txt

## Key facts
- Material Agreements
  Xencor Inc terminated Amended and Restated Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd (effective 2026-09-04).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Genentech, Inc. and F. Hoffmann-La Roche Ltd
  - Effective: 2026-09-04
  source text: On March 4, 2026, Xencor, Inc. (the “Company”) received a notice of termination of an Amended and Restated Collaboration and License Agreement (the “Agreement”), effective as of June 1, 2024, with Genentech, Inc. (“GNE”) and F. Hoffmann-La Roche Ltd (“Roche” and, GNE and Roche, collectively, “Genentech”), pursuant to which Genentech has elected to terminate the Agreement in its entirety for convenience. The effective date of the termination of the Agreement is September 4, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326732/000132673226000023/0001326732-26-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.